Decoy Therapeutics (DCOY) Long-Term Deferred Tax (2014 - 2025)
Decoy Therapeutics (DCOY) posted quarterly Long-Term Deferred Tax of $21.8 million for Q4 2025, up 27.42% year-over-year from $17.1 million in Q4 2024, and up 27.42% quarter-over-quarter from $17.1 million in Q4 2024.
Decoy Therapeutics (DCOY) Long-Term Deferred Tax (2014 - 2025) Analysis & Trends
Decoy Therapeutics (DCOY) has reported Long-Term Deferred Tax for 5 consecutive years, with $21.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Long-Term Deferred Tax rose 27.42% year-over-year to $21.8 million; the TTM figure through Dec 2025 stood at $21.8 million (up 27.42% YoY), while the FY2025 annual figure was $21.8 million, up 27.42% from the prior year.
- Long-Term Deferred Tax climbed to $21.8 million in Q4 2025 per DCOY's latest filing, from $17.1 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $21.8 million in Q4 2025 and bottomed at $17.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Decoy Therapeutics | 1.75 Mn | 1.75 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 21.79 Mn |
| Dec 31, 2024 | 17.10 Mn |
| Mar 31, 2017 | 120,000.00 |
| Dec 31, 2015 | 119,422.00 |
| Sep 30, 2015 | 50,103.00 |
| Jun 30, 2015 | 50,103.00 |
| Mar 31, 2015 | 50,103.00 |
| Dec 31, 2014 | 163,019.00 |